Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
Status: | Active, not recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/7/2018 |
Start Date: | December 2015 |
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and
zoledronic acid with zoledronic acid alone to see how well they work when given after
radiation therapy in treating patients with solitary plasmacytoma of bone. Ixazomib citrate
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Lenalidomide may help the immune system kill abnormal blood cells or cancer cells.
Dexamethasone is a drug used in chemotherapy that may cause tumor cells to die. Zoledronic
acid may prevent bone fractures and reduce bone pain, and may also improve survival. Standard
treatment for this cancer is radiation therapy alone. It is not yet known whether ixazomib
citrate, lenalidomide, dexamethasone and zoledronic acid or zoledronic acid alone is more
effective, and whether adding these treatments after radiation therapy is more effective than
radiation therapy alone in treating patients with solitary plasmacytoma of bone.
zoledronic acid with zoledronic acid alone to see how well they work when given after
radiation therapy in treating patients with solitary plasmacytoma of bone. Ixazomib citrate
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Lenalidomide may help the immune system kill abnormal blood cells or cancer cells.
Dexamethasone is a drug used in chemotherapy that may cause tumor cells to die. Zoledronic
acid may prevent bone fractures and reduce bone pain, and may also improve survival. Standard
treatment for this cancer is radiation therapy alone. It is not yet known whether ixazomib
citrate, lenalidomide, dexamethasone and zoledronic acid or zoledronic acid alone is more
effective, and whether adding these treatments after radiation therapy is more effective than
radiation therapy alone in treating patients with solitary plasmacytoma of bone.
This phase III randomized clinical trial was designed to assess the impact of the addition of
ixazomib, lenalidomide, and dexamethasone to zoledronic acid the multiple myeloma progression
rate at 5 years. A dynamic allocation procedure will be used to allocate an equal number of
patients to each of the treatment arms. This procedure will balance the number of patients
which falls into each of the following categories between the two treatment arms:
1. % of abnormal plasma cells in the bone marrow: 5-9%
2. age < 60; % of abnormal plasma cells in the bone marrow < 5%; and monoclonal
protein/clonal light chains present in the blood or urine
3. age < 60; % of abnormal plasma cells in the bone marrow < 5% and no monoclonal
protein/clonal light chains present in the blood or urine, (MRD+) minimal residual
disease
4. age ≥ 60; % of abnormal plasma cells in the bone marrow < 5%; and monoclonal
protein/clonal light chains present in the blood or urine
5. age ≥ 60; % of abnormal plasma cells in the bone marrow < 5% and no monoclonal
protein/clonal light chains present in the blood or urine, (MRD+) minimal residual
disease
The primary and secondary objectives are described below.
Primary objective
To assess whether ixazomib, lenalidomide, dexamethasone with zoledronic acid is more
promising than zoledronic acid alone in increasing the time before progression to multiple
myeloma.
Secondary objectives
1. To assess changes in minimal residual disease [MRD] by flow cytometry from study entry,
at the completion of treatment, and at 1 year post registration.
2. To assess whether ixazomib, lenalidomide, dexamethasone with zoledronic acid is more
promising than zoledronic acid alone in extending overall survival.
3. To examine the pharmacodynamics effects of treatment on biochemical markers of bone
formation (osteocalcin bone-specific alkaline phosphatase), resorption (serum CTX), and
metabolism (OPG).
Follow-up requirements after documentation of progression to multiple myeloma includes a
maximum of five years following registration.
ixazomib, lenalidomide, and dexamethasone to zoledronic acid the multiple myeloma progression
rate at 5 years. A dynamic allocation procedure will be used to allocate an equal number of
patients to each of the treatment arms. This procedure will balance the number of patients
which falls into each of the following categories between the two treatment arms:
1. % of abnormal plasma cells in the bone marrow: 5-9%
2. age < 60; % of abnormal plasma cells in the bone marrow < 5%; and monoclonal
protein/clonal light chains present in the blood or urine
3. age < 60; % of abnormal plasma cells in the bone marrow < 5% and no monoclonal
protein/clonal light chains present in the blood or urine, (MRD+) minimal residual
disease
4. age ≥ 60; % of abnormal plasma cells in the bone marrow < 5%; and monoclonal
protein/clonal light chains present in the blood or urine
5. age ≥ 60; % of abnormal plasma cells in the bone marrow < 5% and no monoclonal
protein/clonal light chains present in the blood or urine, (MRD+) minimal residual
disease
The primary and secondary objectives are described below.
Primary objective
To assess whether ixazomib, lenalidomide, dexamethasone with zoledronic acid is more
promising than zoledronic acid alone in increasing the time before progression to multiple
myeloma.
Secondary objectives
1. To assess changes in minimal residual disease [MRD] by flow cytometry from study entry,
at the completion of treatment, and at 1 year post registration.
2. To assess whether ixazomib, lenalidomide, dexamethasone with zoledronic acid is more
promising than zoledronic acid alone in extending overall survival.
3. To examine the pharmacodynamics effects of treatment on biochemical markers of bone
formation (osteocalcin bone-specific alkaline phosphatase), resorption (serum CTX), and
metabolism (OPG).
Follow-up requirements after documentation of progression to multiple myeloma includes a
maximum of five years following registration.
Pre-registration eligibility criteria (Step 0)
1. Documentation of Disease: Histologic Documentation of Solitary Bone Plasmacytoma
1. For patients pre-registering after the completion of radiation therapy,
documentation of a bone marrow aspirate and biopsy containing <10% clonal plasma
cells done at most 28 days prior to start of radiation therapy
2. For patients pre-registering before the start of radiation therapy, radiation
therapy scheduled to begin at most 28 days after a bone marrow aspirate and
biopsy were performed containing <10% clonal plasma cells
3. Participants must have disease that is measurable by either serum or urine
evaluation of the monoclonal component or by assay of serum free light chains or
by minimal residual detection. Measurable disease is defined as one or more of
the following:
- serum M protein > 0.5 G/DL, or
- urine M protein >200 MG/24H, and/or
- serum FLC assay: involved FLC level > 10 MG/DL with abnormal serum FLC ratio
- ≥ 50 Plasma cells detectable by multicolor flow cytometry, at a sensitive
level of 10^-4
2. Age ≥ 18 years
3. ECOG Performance Status 0-2
Registration Eligibility Criteria (Step 1)
1. Documentation of Disease:
1. No lytic lesions on skeletal survey and whole body PET/CT other than a single
lesion associated with solitary bone plasmacytoma within 28 days prior to
registration.
2. Participants must have disease that is measurable by either serum or urine
evaluation of the monoclonal component or by assay of serum free light chains or
by minimal residual detection. Measurable disease is defined as one or more of
the following:
- serum M protein > 0.5 G/DL, or
- urine M protein >200 MG/24H, and/or
- serum FLC assay: involved FLC level > 10 MG/DL with abnormal serum FLC ratio
- ≥ 50 Plasma cells detectable by multicolor flow cytometry, at a sensitive
level of 10^-4
2. Prior Treatment
1. No major surgery within 21 days of registration with stabilization or resolution
of surgical adverse events.
2. No investigational agent within 21 days prior to registration
3. No ongoing therapy with corticosteroids greater than 10 mg of prednisone or its
equivalent per day. Please note: Inhaled and topical steroids are permitted.
4. No prior proteasome inhibitor or IMiD use.
5. Prior bisphosphonate use is permitted.
6. For all patients:
- Radiation dose should range from 4500 cGy to 6000 cGy
- No treatment for this disease following radiation therapy
- Registration must be completed within 90 days of completion of radiation
therapy.
3. Not pregnant and not nursing, because this study involves an investigational agent
whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn
are unknown and an agent that has known genotoxic, mutagenic and teratogenic effects.
1. Females of childbearing potential (FCBP), defined as a sexually mature female who
1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been
naturally postmenopausal for at least 24 consecutive months that is, has not had
menses at any time in the preceding 24 consecutive months:
- must have a negative serum or urine pregnancy test with a sensitivity of at
least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of
starting lenalidomide.
- must either commit to continued abstinence from heterosexual intercourse or
begin TWO acceptable methods of birth control, one highly effective method
and one additional effective method AT THE SAME TIME, at least 28 days
before she starts taking lenalidomide.
- must agree to ongoing pregnancy testing.
2. Men must agree to use a latex condom during sexual contact with a FCBP even if
they have had a vasectomy.
4. ECOG Performance Status 0-2
5. Required Initial Laboratory Values within 14 days of registration:
1. Absolute Neutrophil Count (ANC) ≥ 1,500/mm^3
2. Platelet Count ≥ 75,000/mm^3
3. Hemoglobin ≥ 10 g/dL
4. Serum Creatinine < 2.0 mg/dL [176.8 µmol/liter]
5. Serum calcium ≤ 11.5 mg/dL
6. Calc. Creatinine Clearance > 50 mL/min
7. Bilirubin ≤ 1.5 x upper limits of normal (ULN)
8. AST ≤ 2.5 x upper limits of normal (ULN)
6. Intercurrent or Recent Illness
1. If history of prior malignancy, subject should be in complete remission for ≥ 5
years at the time of registration (with the exception of basal cell or squamous
cell carcinoma of the skin treated with local resection).
2. HIV + patients are eligible provided they meet the other eligibility criteria
and:
- CD4+ cells are ≥ 250/mm^3
- There is no history of AIDS defining conditions other than historically low
CD4+ cell count.
- The following antiretroviral agents are not allowed: zidovudine, stavudine,
protease inhibitors, combination pills with pharmacologic boosters.
- Recommended antiretroviral regimens to avoid PK interactions include strand
integrase inhibitors with nucleoside and non-nucleoside reverse
transcriptase inhibitors (for example, dolutegravir given with tenofovir and
emtricitabine).
3. Patients with HBV infection are eligible provided they meet the other eligibility
criteria and:
- There is no evidence of hepatic damage related to HBV infection.
- They have had consistently suppressed HBV viral load to undetectable levels
by PCR for a minimum of 12 months.
4. Patients with HCV infection are eligible provided they meet the other eligibility
criteria and:
- They have previously undergone curative therapy and have no evidence of
active HCV infection.
- They have no evidence of liver damage owing to prior HCV infection.
Patients with active HCV infection should be referred for HCV treatment and
standard radiotherapy for the plasmacytoma.
5. Patients cannot have:
- Known allergy to boron or excipients in the formulation.
- Known GI disease or GI procedure that could interfere with the oral
absorption or tolerance of study drugs including difficulty swallowing.
- Infection requiring systemic antibiotic therapy or other serious infection
within 14 days before registration.
- Diarrhea ≥ Grade 1, based on the NCI CTCAE categorization within 14 days of
registration
- Life-threatening illness unrelated to cancer
- The development of erythema nodosum if characterized by a desquamating rash
while taking thalidomide, pomalidomide, or similar drugs.
7. Peripheral Neuropathy: ≤ Grade 2 Peripheral Neuropathy
8. Adequate cardiac function, defined as:
1. No cardiac arrhythmias within 182 days of registration.
2. No congestive heart failure (CHF) within 182 days of registration.
3. No angina or myocardial infarction within 182 days of registration. In view of
potential cardiac risk with lenalidomide, patients with stable angina will be
excluded.
9. Concomitant Treatment: Patients cannot be on systemic treatment with strong inhibitors
of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (clarithromycin,
telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone) or strong CYP3A
inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital)
within 14 days of registration.
10. QT c< 470 milliseconds (msec) on a 12-lead ECG ≤ 28 days before registration
11. Dental evaluation within 35 days of registration: Complete dental exam; complete
elimination of dental and periodontal pathology including crowns on teeth susceptible
to fracture, extraction of non-restorable or periodontally uncorrectable teeth;
creation of an oral environment that the patient can efficiently maintain in a high
state of health; and oral hygiene instruction to maintain excellent oral health.
We found this trial at
388
sites
401 N Ewing St
Lancaster, Ohio 43130
Lancaster, Ohio 43130
(740) 687-8000
Principal Investigator: Timothy D. Moore
Phone: 740-687-8863
Fairfield Medical Center We are people you know offering care you trust. Serving more than...
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Kelvin P. Lee
Phone: 877-275-7724
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Carter P. Milner
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
1615 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 773-702-9171
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: James R. Egner
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Bellevue, Washington 98005
Phone: 503-216-6300
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: James L. Wade
Phone: 314-996-5569
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Robert L. Schlossman
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Robert L. Schlossman
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 773-702-9171
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Ding Wang
Phone: 888-823-5923
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Michael A. Thompson
Phone: 414-302-2304
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Phone: 406-238-6290
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: James L. Wade
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: James L. Wade
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: James L. Wade
Phone: 618-985-3333
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: James L. Wade
Phone: 618-457-5200
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: James L. Wade
Phone: 618-436-5410
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
Click here to add this to my saved trials
Cincinnati, Ohio 45202
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45211
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45230
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
31500 Telegraph Road
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Clinton Township, Michigan 48038
Principal Investigator: Ding Wang
Phone: 313-916-1784
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Columbus, Ohio 43213
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Click here to add this to my saved trials
810 Jasonway Avenue
Columbus, Ohio 43214
Columbus, Ohio 43214
614/442-3130
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Columbus Oncology and Hematology Associates Inc Columbus Oncology and Hematology Associates is a group of...
Click here to add this to my saved trials
Columbus, Ohio 43222
Principal Investigator: Timothy D. Moore
Phone: 614-234-5433
Click here to add this to my saved trials
5100 W Broad St
Columbus, Ohio 43228
Columbus, Ohio 43228
(614) 544-1000
Principal Investigator: Timothy D. Moore
Phone: 614-566-3275
Doctors Hospital Nationally recognized for care quality and patient safety and satisfaction, Doctors Hospital is...
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
Click here to add this to my saved trials
111 S Grant Ave
Columbus, Ohio 43215
Columbus, Ohio 43215
(614) 566-9000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Grant Medical Center Founded in 1900 in Columbus' downtown, Grant has grown into one of...
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
Click here to add this to my saved trials
Coos Bay, Oregon 97420
Principal Investigator: Alison K. Conlin
Phone: 541-269-8392
Click here to add this to my saved trials
Crestview Hills, Kentucky 41017
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials